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Adipocytes are important players in metabolic health and disease, and disruption of
adipocyte development or function contributes to metabolic dysregulation. Hence,
adipocytes are significant targets for therapeutic intervention in obesity and metabolic
syndrome. Plants have long been sources for bioactive compounds and drugs. In
previous studies, we screened botanical extracts for effects on adipogenesis in vitro
and discovered that an ethanolic extract of Artemisia scoparia (SCO) could promote
adipocyte differentiation. To follow up on these studies, we have used various separation
methods to identify the compound(s) responsible for SCO’s adipogenic properties.
Fractions and subfractions of SCO were tested for effects on lipid accumulation and
adipogenic gene expression in differentiating 3T3-L1 adipocytes. Fractions were also
analyzed by Ultra Performance Liquid Chromatography- Mass Spectrometry (UPLC-MS),
and resulting peaks were putatively identified through high resolution, high mass accuracy
mass spectrometry, literature data, and available natural products databases. The
inactive fractions contained mostly quercetin derivatives and chlorogenates, including
chlorogenic acid and 3,5-dicaffeoylquinic acid, which had no effects on adipogenesis
when tested individually, thus ruling them out as pro-adipogenic bioactives in SCO.
Based on these studies we have putatively identified the principal constituents
in SCO fractions and subfractions that promoted adipocyte development and fat
cell gene expression as prenylated coumaric acids, coumarin monoterpene ethers,
6-demethoxycapillarisin and two polymethoxyflavones.
Keywords: adipocyte, plants-medicinal, botanical extract, adipogenesis, fat cell, activity-guided fractionation,
3T3-L1 adipocyte

INTRODUCTION
Obesity, one of the great public health challenges of our time, is a major risk factor for type 2
diabetes mellitus (T2DM) and cardiovascular disease (1, 2). Inhibition of adipocyte differentiation
was once viewed as a promising therapeutic strategy for preventing or treating obesity and its
metabolic consequences. However, it is now known that obese and insulin resistant states are
associated with impaired adipogenesis and that limiting adipose tissue expansion leads to ectopic
lipid deposition and metabolic dysregulation (3–6). Thiazolidinediones (TZDs) are a class of
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antidiabetic drugs that both enhance adipogenesis and
improve whole-body insulin sensitivity in the presence of
increased adipose tissue mass (7). Clinical use of TZDs
has declined substantially since 2007, in response to
concerns over safety and side effects that may not occur
from botanical alternatives of TZDs. Nevertheless, adipocyte
differentiation continues to be a therapeutic target of interest
for intervention in metabolic related diseases including obesity
and T2DM.
Botanicals have a long history of medicinal use in many
cultures, and countless drugs have been derived from plants,
including metformin, a compound derived from French lilac
that was used in traditional herbal medicine for centuries
to lower blood glucose (8, 9). Currently, metformin is the
preferred first line treatment and most commonly prescribed
medication for T2DM. Since plant extracts represent a potential
source of novel therapeutic compounds, we have performed
screening experiments to identify botanical extracts that
could enhance adipocyte development. We identified an
extract of Artemisia scoparia (SCO) as having positive effects
on adipocyte differentiation and endocrine function both
in vitro and in vivo (10, 11). We have also described
the inhibition of lipolysis, both in vitro and in vivo, as
an additional mechanism involved in SCO’s metabolically
beneficial effects (12). The focus of the current study was
to identify the constituents of SCO responsible for its
adipogenic effects.
Initially, three crude partitions of the SCO parent extract
were generated with water, hexane, and ethyl acetate (W, H, and
EA). Each of these crude fractions was tested for the ability to
promote adipogenesis in 3T3-L1 cells by assessing both lipid
accumulation and adipocyte marker gene expression. Next, we
performed successive rounds of fractionation and testing to
separate active from inactive fractions. Ultra Performance Liquid
Chromatography- Mass Spectrometry (UPLC-MS) analysis was
performed on all fractions, and compounds were putatively
identified using high resolution, high mass accuracy mass
spectrometry, literature data, and available databases. We
determined that the predominant constituents identified in the
inactive fractions were chlorogenates and quercetin derivatives,
while the active fractions primarily contained prenylated
coumaric acids (PCAs), coumarin monoterpene ethers, 6demethoxycapillarisin, as well as two polymethoxyflavones. In
addition, we observed that some fractions with no common
compounds were active in our adipogenesis assay, suggesting
that more than one component in SCO can promote adipocyte
differentiation. Lipid accumulation assays have been used to
screen botanical extracts for effects on adipocyte differentiation
(13–16) and to isolate anti-adipogenic compounds from natural
products (17, 18), but this is the first study, to our knowledge,
to use such screening assays to identify fractions of a
botanical extract capable of promoting adipogenesis. Although
additional efforts will be required to unequivocally identify
pure bioactive compounds from SCO, our study has ruled out
several bioactives of SCO and revealed groups of compounds
that account for the ability of this plant extract to promote
adipocyte development.
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Source and Preparation of A. scoparia
Extract and Fractions
Ethanolic extracts were prepared from greenhouse-grown plants
as described previously (11, 12). The ethanolic extract of
Artemisia scoparia (SCO, 10 g) was dissolved in water (200 ml)
and partitioned 3 times with hexane (3 × 200 ml). Hexane
partitions were combined and dried by rotary evaporation to
produce the H crude fraction. The water portion was further
partitioned 3 times with ethyl acetate (3 × 200 ml). The ethyl
acetate partitions were combined and dried by rotary evaporation
to produce the EA crude fraction. Remaining water was dried of
residual solvents by rotary evaporation and by freeze drying to
produce the W crude fraction.
The SCO EA crude fraction was fractionated using a
semipreparatory high-performance liquid chromatography
(HPLC) system consisting of WatersTM Alliance e2695
Separations Module and 2998 Photodiode Array Detector
with a Phenonmenex Synergi 4 µm 80 Å Hydro-RP column 250
× 21.2 mm. The mobile phases consisted of two components:
Solvent A (0.5% ACS grade acetic acid in double distilled
de-ionized H2 O), and Solvent B (acetonitrile). Separation was
completed using a gradient run of 25% B in A to 95% B over
35 min at a flow rate of 8 mL/min. Five fractions, H1–H5,
were obtained.
The SCO EA crude fraction was also subjected to fast
centrifugal partition chromatography (FCPC) fractionation
using countercurrent chromatography separation (CCS) with a
biphasic solvent system (HEMWat +3) composed of Hexanes/
Ethyl-Acetate/ Methanol/ Water (6:4:6:4 v/v) on a Kromaton
(Annonay, France) bench-scale fast centrifugal partition
chromatography system FCPC1000, v 1.0, equipped with a
1,000 ml volume rotor. For fractionation, the column was first
filled with the lower phase 40 ml/min using a Chrom Tech R
PR-Pump while rotating at 300 rpm. The system was then
equilibrated with upper phase at a flow rate of 10 ml/min and
750 rpm. A 2 g sample of SCO was suspended in 10 ml of each
phase of the solvent system used for separation, sonicated and
filtered (Millipore filter type NY11). The sample was injected
with the upper phase flow at 10 ml/min and rotor rotation of 750
rpm. UV detection was performed at 254 nm using a Visacon
VUV-24 detector, and fractions were collected manually. Ten
fractions, F1–F10, were obtained.
F2 of the above FCPC fractions was further fractionated
using a semipreparatory HPLC system consisting of WatersTM
600 Controller and 486 Tunable Absorbance Detector with a
Phenonmenex Synergi 10 µm 80 Å MAX-RP column 250 ×
21.2 mm. The mobile phases consisted of two components:
Solvent A (0.1% ACS grade acetic acid in double distilled deionized H2 O), and Solvent B (100% acetonitrile). For the initial
separation, a gradient run of 40% B in A to 70% B over
35 min was used at a flow rate of 15 ml/min. SCO fraction
2–2 was further fractionated using the same semipreparatory
HPLC system with a Phenomenex Kinetex 5 µm C18 100 Å LC
column 250 × 10.0 mm. The mobile phases consisted of two
components: Solvent A (0.1% ACS grade formic acid in double
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distilled de-ionized H2 O), and Solvent B (100% acetonitrile). For
the secondary separation, a gradient run of 40% B in A to 80% B
over 80 min was used at a flow rate of 5 ml/min. Fractions were
collected manually as defined by UV (254 nm) peak designations
for both separations.

10% FBS containing 0.425 µM insulin, and cells were again
treated with DMSO vehicle or extract/fractions. Cells were either
harvested for RNA purification or fixed and stained for lipid
accumulation. DMEM, IBMX, dexamethasone, insulin, and
DMSO were purchased from Sigma-Aldrich (St. Louis, MO), and
FBS from Hyclone (GE Healthcare Life Sciences, Logan, UT).

UPLC/MS Analysis of A. scoparia Extracts
Compounds in samples were separated and analyzed by a
UPLC/MS system including the Dionex R UltiMate 3000 RSLC
ultra-high pressure liquid chromatography system, consisting
of a workstation with ThermoFisher Scientific’s Xcalibur
v. 4.0 software package combined with Dionex R ’s SII LC
control software, solvent rack/degasser SRD-3400, pulseless
chromatography pump HPG-3400RS, autosampler WPS3000RS, column compartment TCC-3000RS, and photodiode
array detector DAD-3000RS. After the photodiode array detector,
the eluent flow was guided to a Q Exactive Plus Orbitrap highresolution high-mass-accuracy mass spectrometer (MS). Mass
detection was full MS scan with low energy collision induced
dissociation (CID) from 100 to 1,000 m/z in either positive or
negative ionization mode with electrospray ionization (ESI)
interface. Sheath gas flow rate was 30 arbitrary units, auxiliary
gas flow rate was 7, and sweep gas flow rate was 1. The spray
voltage was 3,500 volts (−3,500 for negative ESI) with a capillary
temperature of 275◦ C. The mass resolution was 70,000 or higher.
Substances were separated on a PhenomenexTM Kinetex C8
reverse phase column, size 100 × 2 mm, particle size 2.6 µm,
pore size 100 Å. The mobile phase consisted of 2 components:
Solvent A (0.5% ACS grade acetic acid in LCMS grade water,
pH 3–3.5), and Solvent B (100% acetonitrile, LCMS grade).
The mobile phase flow was 0.20 ml/min, and a gradient mode
was used for all analyses. The initial conditions of the gradient
were 95% A and 5% B; for 30 min the proportion reaches 5% A
and 95% B which was kept for the next 8 min, and during the
following 4 min the ratio was brought to initial conditions. An
equilibration interval of 8 min was included between subsequent
injections. The average pump pressure using these parameters
was typically around 3,900 psi for the initial conditions. Putative
formulas of natural products were determined by performing
isotope abundance analysis on the high-resolution mass spectral
data with Xcalibur v. 4.0 software and reporting the best fitting
empirical formula. Database searches were performed using
www.reaxys.com (Elsevier RELX Intellectual Properties SA) and
SciFinder (scifinder.cas.org, American Chemical Society).

RNA Purification and Gene Expression
Analysis
Three or four days after induction, RNA was purified from
harvested cells using the RNeasy mini-kit (Qiagen, Hilden,
Germany) and reverse-transcribed using the High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Foster
City, CA), according to manufacturers’ instructions. Quantitative
PCR (qPCR) gene expression analyses were performed using
primers from Integrated DNA Technologies (Skokie, IL) (primer
sequences shown in Table 1) and SYBR Premix (Takara Bio USA,
Mountain View, CA). Assays were run on the Applied Biosystems
7900HT system and data were analyzed with SDS 2.3 software.
Cycling conditions were as follows: 2 min, 50◦ C; 10 min, 95◦ C;
40 cycles of 15 s at 95◦ C and 1 min at 60◦ C; dissociation stage:
15 s, 95◦ C; 15 s, 60◦ C; 15 s, 95◦ C. Relative quantities of target
genes were normalized to those of the reference gene, non-POUdomain-containing, octamer binding protein (Nono).

Lipid Accumulation
Four days after the induction of differentiation, cells were fixed
with 10% neutral buffered formalin obtained from Thermo Fisher
Scientific (Waltham, MA), and stained with Oil Red O (ORO), as
described previously (11). Stain was eluted in isopropyl alcohol
(IPA), and absorbance measured at 520 nm for quantitation.
ORO and IPA were purchased from Sigma-Aldrich.

Statistics
Statistical analyses were performed using GraphPad Prism
software (La Jolla, CA, USA). For control vs. SCO or parent
fraction positive controls, t-tests were performed with a threshold
for statistical significance of p < 0.05. Analysis of each test
fraction or subfraction was performed using one-way ANOVA
with Dunnett’s multiple comparisons test (each dose compared
to DMSO control).

RESULTS

Cell Culture and Treatments

We have previously shown that SCO exerts robust proadipogenic effects in the 3T3-L1 preadipocyte cell line and
that SCO can activate the PPARγ ligand binding domain in
HEK 293 cells when examined using a Gal4 DNA-bindingluciferase assay (10, 11). In addition to these in vitro studies,
we have also demonstrated that SCO has some protective
effects against diet-induced obesity in mice (10, 11). We
predict that the metabolically beneficial effects of SCO in vivo
might be mediated by its ability to increase adipogenesis.
In order to identify bioactive components of SCO, crude
partitions of SCO (water, hexane, and ethyl acetate) and their

Murine 3T3-L1 preadipocytes were grown to confluence
as described previously (11). Two days post confluence,
differentiation was induced using half-strength standard
methylxanthine-dexamethasone-insulin
(MDI)
cocktail
(0.25 mM
3-isobutylmethylxanthine
(IBMX),
0.5 mM
dexamethasone and 0.85 µM insulin) in high-glucose Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS). Extracts or fractions dissolved in
dimethylsulfoxide (DMSO), or DMSO vehicle only, were added
to the differentiation medium. Forty-eight hours after induction
of differentiation, medium was replaced with DMEM plus
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fraction. The hexane (H) and water (W) fractions contained
non-overlapping subsets of peaks (peaks 1–6 predominant in
W, and peaks 16–23 in H). W also contained 5 additional
peaks (peaks 24–28) that were not detected in SCO, indicating
a low concentration of the corresponding compounds in the
parent extract.
In order to determine which compound(s) or combination(s)
of compounds could enhance adipogenesis, we tested the
crude partitions for effects on lipid accumulation and on

subfractions were tested for effects on adipogenesis in 3T3L1 cells. An outline diagram of the fractionation scheme is
shown in Figure 1.
LC-MS analysis was performed on the parent SCO extract and
the three crude partitions (Figure 2). Twenty-eight constituent
compounds were detected, and putatively identified (Table 2).
The ethyl acetate fraction (EA) was found to have an enriched
profile relative to that of the parent SCO extract, and all 23
compounds detected in SCO were also present in the EA

TABLE 1 | qPCR primer sequences for gene expression analyses.
Forward Primer, 5′ -3′

Gene name and symbol

Reverse Primer, 5′ -3′

Adiponectin (Adipoq)

TGTCTGTACGATTGTCAGTGG

GCAGGATTAAGAGGAACAGGAG

Adipocyte protein 2 (aP2)/Fatty acid binding protein 4 (Fabp4)

CCCTCCTGTGCTGCAGCCTTTC

GTGGCAAAGCCCACTCCCACTT

Fatty acid synthase (Fasn)

GGCATCATTGGGCACTCCTT

ACCAACAGCTGCCATGGATC

Non-POU-domain-containing, octamer binding protein (Nono)

CATCATCAGCATCACCACCA

TCTTCAGGTCAATAGTCAAGCC

FIGURE 1 | Artemisia scoparia extracts, fractions, and subfractions progeny. Shaded fractions and subfractions were active. For crude fractions: light shading
indicates significant enhancement of lipid accumulation as measured by ORO staining, while dark shading indicates FC > 1.5 in ORO staining vs. controls. For HPLC
fractions of EA, light shading indicates significant effects on ORO staining and adipogenic gene expression at 20 µg/ml dose; dark shading indicates significant effects
on ORO staining and gene expression at 5 and 20 µg/ml doses. For FCPC fractions of EA, light shading indicates significant effects on ORO staining at both doses
tested (2 and 10 µg/ml); dark shading indicates fractions that enhanced ORO staining by 2-fold or greater. For subfractions of EA-F2, light shading indicates a
significant effect on ORO staining at any dose and FC < 1.5, while dark shading indicates fractions that enhanced ORO staining by 1.5-fold or more at any dose. For
subfractions of F2-2, shading indicates significant increases in ORO staining and in AdipoQ and Fabp4 gene expression at both doses tested.
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FIGURE 2 | Total ion current [(-)ESI MS] chromatograms of SCO (Parent extract) and its water, ethyl acetate, and hexane fractions.

identification for the most active HPLC and FCPC fractions
are shown in Figure S1. Of the five HPLC fractions tested,
H4 and H5 produced a robust induction in lipid accumulation
and adipogenic gene expression, H3 produced more modest
positive effects, and H1 and H2 were inactive (Figure 4). In
the lipid accumulation assay (Figures 4A,B), 5 and 20 µg/ml
doses of H4 and H5 enhanced staining even more than
their parent EA fraction. At the lowest dose (1 µg/ml) H5
produced a more modest increase in ORO staining, and
the effect of H4 was not significant. H1 and H2 had no
significant effects on lipid accumulation at any of the doses
tested. Effects of the HPLC fractions on adipogenic gene
expression closely mirrored the ORO results, with the 5 and
20 µg/ml doses of H4 and H5, as well as the 20 µg/ml dose
of H3 strongly inducing the expression of AdipoQ, Fabp4,
and Fasn, and H1 and H2 having no significant effects on
any of the genes (Figure 4C). H3 consisted almost exclusively
of peaks 7, 8, and 9 (all identified as prenylated cinnamic
acids and/or sesquiterpene lactones with a m/z of 331 [MH]+ ). Peaks identified as prenylated coumaric acid or Artepillin
A (m/z of 315 [M-H]+ ) were the most abundant in both
H4 and H5. H4 also contained relatively large amounts of
peaks 11, 12, 13, and 15, whereas H5 had significant amounts
of peaks 20 and 22, as well as an additional compound
putatively identified as a prenylated acetophenone. In the inactive
fractions (H1 and H2), we observed the presence of peaks
#1–6 (chlorogenic acid, caffeic acid glycosides, rutin, quercetin

the expression of several genes known to be induced during
adipocyte development. These genes include the adipocyte
specific hormone adiponectin (AdipoQ), fatty acid binding
protein 4/adipocyte protein 2 (Fabp4), and fatty acid synthase
(Fasn). Results are shown in Figure 3A (lipid accumulation) and
Figure 3B (adipogenic gene expression). Lipid accumulation,
as measured by ORO staining, was not affected by treatment
with 1, 5, or 20 µg/ml of W. Fractions H and EA both
significantly enhanced lipid accumulation at all three doses
tested, with the 20 µg/ml dose of H and the 5 and 20 µg/ml
doses of EA showing effects similar to that of the SCO
parent extract. Adipogenic gene expression was consistent
with the lipid accumulation results, with no effect of W on
the expression of AdipoQ, Fabp4, or Fasn, and clear dosedependent increases in all three genes with H and EA. However,
the effects of H and EA at the low dose (1 µg/ml) were
not significant. The active hexane fraction (H), whose most
abundant components were peaks 16, 18, 20, and 22, was
only slightly less active than the ethyl acetate fraction (EA),
which contained all 23 of the peaks identified in SCO. The
inactive water fraction (W) contained mainly chlorogenic acid
(peak 1) and caffeic acid and quercetin derivatives, including
two dicaffeoylquinic acids (peaks 2–6) (LC-MS data shown
in Figure 2).
To further characterize the bioactivity of SCO, two sets of
fractions were prepared from EA: one by HPLC and another
by FCPC (Figure 1). LC-MS analysis and putative compound
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TABLE 2 | Preferred molecular formulas and putative identification of compounds detected by UPLC/MS in SCO: Preferred molecular formulas were determined from
isotope abundance analysis (Xcalibur v. 4.0 software), and compounds were putatively identified through searches of natural product databases.
Peak #

[M – H] (Preferred mol. formula)

Reported from Artemisia species (Reaxys.com)

1

353.0873 (C16 H18 O9 )

Chlorogenic acid

2

311.0769 (C14 H16 O8 )

No

3

609.1457 (C27 H30 O16 )

Rutin

4

463.0875 (C21 H20 O12 )

Quercetin-glycoside

5

515.1181 (C25 H24 O12 )

Di-caffeoyl-quinic acid

6

515.1181 (C25 H24 O12 )

Di-caffeoyl-quinic acid

7, 8, 9

331.1547/331.1548 (C19 H24 O5 )

Prenylated cinnamic acid(s) and/or Sesquiterpene lactone(s)

10

303.1599 (C18 H24 O4 )

Prenylated acetophenone

11

285.0399 (C15 H10 O6 )

6-Demethoxycapillarisin

Caffeic acid glycosides

12

359.0772 (C18 H16 O8 )

Trihydroxy-tri-MeO-flavones

13

373.1653 (C21 H26 O6 )

A coumarin monoterpene ether and/or a lignan

14

343.0823 (C18 H16 O7 )

A Dihydroxy-tri-MeO-flavone

15

373.1654 (C21 H26 O6 )

A coumarin monoterpene ether and/or a lignan

16

315.1601 (C19 H24 O4 )

Prenylated coumaric acid or Artepillin A

17

315.1601 (C19 H24 O4 )

Prenylated coumaric acid or Artepillin A

18

315.1601 (C19 H24 O4 )

Prenylated coumaric acid or Artepillin A

19

373.1654 (C21 H26 O6 )

A coumarin monoterpene ether

20

415.1759 (C23 H28 O7 )

(Epi-)Magnolin

21

357.1713 (C21 H26 O5 )

Prenylated coumaric acid

22

357.1713 (C21 H26 O5 )

Prenylated coumaric acid

23

299.1649 (C19 H24 O3 )

Artepillin C or a steroid

Reported as natural product (Reaxys.com)

Schisandrin type of structures; Lignan derivatives

24

387.1662 (C18 H28 O9 )

No

A hydroxyphenyl monosaccharide

25

755.2044 (C33 H40 O20 )

No

Quercetin trisaccharide

26

471.1148 (C20 H24 O13 )

No

A coumarin disaccharide

27

695.1478 (C30 H32 O19 )

No

A flavone malonyldisaccharide

28

427.1611 (C20 H28 O10 )

No

A hydroxybenzoyl disaccharide

lactones, 6-demethoxycapillarisin, polymethoxyflavones, and
coumarin monoterpene ethers promoted adipogenesis in 3T3L1 cells, while fractions containing chlorogenates and quercetin
derivatives did not. A compound detected in our inactive
fractions, 3,5-dicaffeoylquinic acid (peak 5), has previously been
isolated from A. scoparia and shown to have anti-inflammatory
effects in activated mast cells (19). To determine whether it
could regulate adipogenesis in our experimental conditions,
we treated differentiating 3T3-L1 cells with commercially
obtained 3,5-DCQA and did not observe any effects on lipid
accumulation or adipogenic gene expression (Figure 6). While
there is substantial evidence that chlorogenic acid (CGA,
peak 1) has beneficial effects on metabolic parameters in
vivo (20), pro- and anti-adipogenic, as well as neutral effects
on adipocyte differentiation have been reported for CGA
and for botanical extracts containing CGA (21–27). In our
hands, CGA had no effect on lipid accumulation during
3T3-L1 differentiation (data not shown), consistent with our
findings that the SCO fractions containing CGA did not
enhance adipogenesis. Previous SCO fractionation efforts in our
laboratory have yielded several pure compounds corresponding
to peaks in the W fraction, and these also failed to promote
adipocyte differentiation.

glycoside and dicaffeoylquinic acids). These results are consistent
with those obtained from our analysis of the crude fractions (EA,
H, and W).
FCPC was used as an alternative method of fractionation to
HPLC because larger amounts of extract could be separated in
each run. Quantitation of ORO staining for the FCPC fractions
of EA is shown in Figure 5 (images of stained plates are shown
in Figure S2). The most active FCPC fractions of EA were F2, F3,
and F6. F2 and F3 enhanced lipid accumulation by at least twofold at both doses tested (2 and 10 µg/ml), while fold-changes
for F6 were slightly lower; F4, F5, and F7 significantly increased
ORO staining, but to a lesser degree than F2, F3, or F6. F8 and
F9 were inactive (with the exception of very slight enhancement
of lipid accumulation at the higher dose of F9). Once again,
peaks 1 through 6 were the major constituents of the inactive
fractions (F8 and F9), while the active fractions (F2 through
F7) contained combinations of peaks 8, 9, 11–13, 15, 16, 18,
20, and 22.
To summarize, adipogenesis experiments with SCO crude
partitions (EA, H, and W) and with HPLC or FCPC fractions
of EA provided highly consistent results demonstrating that
the fractions containing predominantly prenylated coumaric
acid derivatives, prenylated cinnamic acids and/or sesquiterpene
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FIGURE 3 | Hexane (H) and ethyl acetate (EA) fractions of SCO enhance adipogenesis in 3T3-L1 cells. Cells were induced to differentiate using half-strength MDI
cocktail containing DMSO vehicle, 50 µg/ml of SCO, or 1, 5, or 20 µg/ml of W, H, or EA. Four days after induction, cells were fixed and stained with Oil Red O. Staining
was quantitated by measuring absorbance in isopropanol eluates (A). Three days after induction, cells were harvested, RNA was isolated and subjected to reverse
transcription and qPCR to assess expression of the adipogenic genes AdipoQ, Fabp4, and Fasn (B). All data are expressed as fold-change vs. vehicle controls. *p <
0.05, § p < 0.01, † p < 0.001, ‡ p < 0.0001 vs. DMSO controls. Results have been replicated in two additional experiments on independent batches of cells.

principal constituent of F2-6 was peak 22 (another prenylated
coumaric acid).
Since F2-2 contained a higher number of peaks than F2-3
or F2-6, we further fractionated F2-2 into 7 subfractions (22-1, 2-2-2, 2-2-3, 2-2-4A, 2-2-4B, 2-2-5, and 2-2-6) that were
examined for their potential ability to modulate adipogenesis.
Quantitation of ORO staining for F2-2 subfractions is shown in
Figure 8 and images of the stained plates are in Figure S4. F22-1, 2-2-2, and 2-2-3 slightly enhanced lipid accumulation at the
highest dose tested, but did not increase expression of AdipoQ
or Fabp4. In contrast, F2-2-4a, 2-2-4b, 2-2-5, and 2-2-6 robustly
promoted lipid accumulation and adipogenic gene expression at
both doses tested. Although the four main constituents we had
identified in F2-2 were not further resolved by this subsequent
fractionation, they did, as a group, segregate into the active
subfractions (F2-2-4a, 2-2-4b, 2-2-5, and 2-2-6). The inactive
subfractions, in contrast, contained peaks that were much
less abundant in the parent F2-2 fraction. These observations

Having conclusively determined the lack of activity of SCO
fractions containing chlorogenates and quercetin derivatives,
we proceeded to subfractionate F2, as this fraction contained
relatively large amounts of peaks 16, 18, 20, and 22. Subfractions
F2-0 through F2-7, plus F2-E were tested for effects on lipid
accumulation in differentiating 3T3-L1 cells (LC-MS data for
F2 shown in Figure S1). Quantitation of lipid staining by ORO
is shown in Figure 7 (Figure S3 contains images of stained
plates). All subfractions of F2 enhanced lipid accumulation to
some degree, with F2-2, F2-3, and F2-6 showing the most
activity. As was the case with the HPLC fractions of EA, we
observed that fractions with little or no overlap were capable
of enhancing adipogenesis. Indeed, LC-MS analysis determined
that F2-2 was comprised of peaks 15, 16, and 17. While F2-3
and F2-6, both very active in promoting adipogenesis, were not
pure single compounds, they each had a single very dominant
peak. In the case of F2-3, that peak was peak 17 (putatively
identified as prenylated coumaric acid or Artepillin A), while the
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FIGURE 4 | Adipogenesis in 3T3-L1 cells is enhanced by HPLC subfractions of EA. Cells were induced to differentiate using half-strength MDI cocktail containing
DMSO vehicle, 20 µg/ml of EA, or 1, 5, or 20 µg/ml of each HPLC subfraction of EA. Four days after induction, cells were fixed and stained with Oil Red O (A);
absorbance was measured in isopropanol eluates to quantitate staining (B). Cells were also harvested for RNA isolation and reverse transcription, expression of
adiponectin (AdipoQ), aP2 (Fabp4), and FAS (Fasn) were assayed by qPCR (C). All data expressed as fold-change vs. DMSO vehicle controls. *p < 0.05,§ p < 0.01,
† p < 0.001, ‡ p < 0.0001 vs. DMSO controls.

remains significant. Adipose tissue is an attractive target
for preventive and therapeutic strategies that should include
botanical bioactives and their derivatives. Our group has
identified an extract of Artemisia scoparia (SCO) as an enhancer
of adipocyte differentiation and function in vitro, and of wholebody insulin sensitivity in vivo (10, 11). To better understand
the mechanisms involved in SCO’s effects on adipogenesis and to
identify individual compounds in SCO that may be responsible
for those effects, we performed activity-guided fractionation,
in which fractions and subfractions were tested for bioactivity
in differentiating 3T3-L1 adipocytes, and analyzed by LC-MS
for composition. The ability of SCO to enhance adipogenesis
was measured by examining both lipid accumulation and the
expression of genes induced during adipocyte development.
Crude partitioning of SCO yielded two fractions with proadipogenic activity (H and EA), and one inactive fraction (W).

provide further evidence that the combination of F2-2’s
dominant compounds promotes adipogenesis. Interestingly,
although peak 9 (prenylated cinnamic acids and/or SQLs)
was present only in very small amounts in the parent F22 fraction, it was a major constituent of F2-2’s inactive
fractions. Indeed, peak 9 and additional higher-retentiontime (RT) peaks also identified as C19 H24 O5 were found
to be the predominant constituents of F2-2-1, F2-2-2, and
F2-2-3 (data not shown), indicating that these peaks are
not responsible for the pro-adipogenic effects of SCO or its
active fractions.

DISCUSSION
As the current obesity epidemic continues unabated, the
need for novel interventions to enhance metabolic health
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Some of the major constituent compounds in the inactive
water partition (W) were the lower retention time peaks
(higher polarity) found in the SCO parent extract, putatively
identified as chlorogenates and quercetin derivatives, including
dicaffeoylquinic acids. These classes of compounds have been
found to improve insulin sensitivity and metabolic function,
but they appear to do so while also inhibiting adipogenesis

(24, 26, 28–38). We observed no enhancement or inhibition of
adipogenesis in cells treated with the W fraction or with the pure
compounds CGA and 3,5-DCQA.
The hexane partition (H), in contrast, was quite active,
and contained mostly the higher retention time peaks (nonpolar) of the SCO parent extract. The four most abundant
peaks were putatively identified as three prenylated coumaric

FIGURE 5 | Adipogenesis in 3T3-L1 cells is enhanced by FCPC subfractions
of EA. Cells were induced to differentiate using half-strength MDI cocktail
containing DMSO vehicle, 20 µg/ml of EA, or 2 or 10 µg/ml of each FCPC
subfraction of EA. Four days after induction, cells were fixed and stained with
Oil Red O. Staining was quantitated by measuring absorbance in isopropanol
eluates. All data expressed as fold-change vs. DMSO vehicle controls. *p <
0.05,§ p < 0.01, † p < 0.001, ‡ p < 0.0001 vs. DMSO controls. Images of the
stained plates are shown in Figure S2. The same fractions were found to be
active in two independent experiments.

FIGURE 7 | Adipogenesis in 3T3-L1 cells is enhanced by subfractions of
EA-F2. Cells were induced to differentiate using half-strength MDI cocktail
containing DMSO vehicle, 10 µg/ml of EA-F2, or 2 or 10 µg/ml of each EA-F2
subfraction. 4 days after induction, cells were fixed and stained with Oil Red O.
Staining was quantitated by measuring absorbance in isopropanol eluates. All
data expressed as fold-change vs. DMSO vehicle controls. *p < 0.05, § p <
0.01, † p < 0.001, † p < 0.0001 vs. DMSO controls. Images of the stained
plates are shown in Figure S3.

FIGURE 6 | 3,5-DCQA does not enhance adipogenesis in 3T3-L1 cells. Cells were induced to differentiate using half-strength MDI cocktail containing DMSO vehicle,
50 µg/ml SCO, or 1, 5, or 20 µg/ml of 3, 5-dicaffeoylquinic acid (DCQA). (A) 4 days after induction, cells were fixed and stained with Oil Red O. Staining was
quantitated by measuring absorbance in isopropanol eluates. (B) 3 days after induction, cells were harvested for RNA purification and reverse transcription; relative
expression of AdipoQ, Fabp4, and Fasn were assayed by qPCR. All data expressed as fold-change vs. DMSO vehicle controls. † p < 0.001, ‡ p < 0.0001 vs. DMSO
controls. Three independent experiments were performed with the same results.
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retention time than the peak in our fractions, so we ruled
out magnolin as a bioactive in our SCO fractions. The H
fraction was also predictably enriched in four fatty acids
(linolenic, linoleic, palmitic, and oleic). Although linoleic
and linolenic acids are known to be agonists of PPARγ
(16, 39, 40), our data from subsequent subfractions do not
support a major role for these compounds in the adipogenic
activity of SCO. In addition, unpublished experiments from
our laboratory showed no effect of linoleic acid on 3T3-L1
adipocyte differentiation.
Given that EA contained all 23 peaks found in SCO, we
opted to subfractionate this partition for further testing,
and confirmed that chlorogenates and quercetin derivatives
segregated into subfractions that were ineffective in enhancing
3T3-L1 differentiation. However, subfractions rich in other
compounds (prenylated coumaric and cinnamic acids,
coumarin monoterpene ethers, 6-demethoxycapillarisin,
polymethoxyflavones, and possibly sesquiterpene lactones)
displayed pro-adipogenic activity. We also observed several
active fractions with no overlap in chemical composition,
indicating the presence of several individual compounds in
SCO capable of improving adipocyte differentiation. The
identification of prenylated coumaric acids (PCAs) as putative
adipogenic agents in SCO was particularly interesting given
that the PCAs drupanin, baccharin, and artepillin C have
been identified as major bioactive constituents of propolis
and that propolis can enhance differentiation of 3T3-L1 cells
(41, 42). In particular, Artepillin C, which is found both in
Brazilian green propolis and in the plant from which it is
derived, Baccharis dracunculifolia, has been shown to promote
adipogenesis through activation of PPARγ (43). Although the
formulas of SCO compounds thought to be PCAs in our extracts
and fractions are different from known adipogenic PCAs, it is
certainly possible that SCO contains distinct PCAs with similar
properties. As for the other compounds putatively identified in
SCO’s adipogenic fractions, little is known about their effects
on adipogenesis. Polymethoxyflavones are a large group of
phytochemicals with a wide range of bioactivity. However,
the reported effects of polymethoxyflavones on adipocyte
differentiation and insulin resistance are not consistent (44–49).
Sesquiterpene lactones, identified as possible constituents of
several pro-adipogenic SCO fractions (H3, H4, F3, F5, F6,
F7), have been reported to have both pro- and anti-adipogenic
activities for different compounds in this class (50–55).
In mature 3T3-L1 adipocytes, the coumarin monoterpene
auraptene, isolated from citrus, increases adiponectin levels
and the proportion of high-molecular-weight adiponectin, and
also reduces levels of the pro-inflammatory cytokine monocyte
chemoattractant protein 1 (MCP-1) (56). To our knowledge,
nothing is known about the effects of this class of compounds on
adipocyte differentiation.
The data presented here highlight some of the challenges
of investigating the bioactivity of botanical extracts. Identifying
individual compounds in such complex mixtures involves
methods that are generally time-consuming and expensive.
Definitive identification of the constituents of our active
SCO fractions will require large amounts of highly purified

FIGURE 8 | Adipogenesis in 3T3-L1 cells is enhanced by subfractions of
EA-F2-2. Cells were induced to differentiate using half-strength MDI cocktail
containing DMSO vehicle, 10 µg/ml of F2-2, or 5 or 20 µg/ml of each EA-F2
subfraction. (A) 4 days after induction, cells were fixed and stained with Oil
Red O. Staining was quantitated by measuring absorbance in isopropanol
eluates. (B) 3 days after induction, cells were harvested for RNA purification
and reverse transcription; relative expression of AdipoQ and Fabp4 were
assayed by qPCR. All data expressed as fold-change vs. DMSO vehicle
controls. *p < 0.05, § p < 0.01, † p < 0.001, ‡ p < 0.0001 vs. DMSO controls.
Images of the stained plates are shown in Figure S4.

acid peaks, plus one peak tentatively identified as a lignan
derivative. The preferred formula of this peak based on
high resolution, high mass accuracy mass spectral analysis
was C23 H28 O7 . This is the formula for the lignan magnolin,
among other natural products, which has been reported in
Artemisia species; however, analysis of a commercially obtained
standard revealed that magnolin standard had a different

Frontiers in Nutrition | www.frontiersin.org

10

March 2019 | Volume 6 | Article 18

Boudreau et al.

SCO Fractions Promote Adipogenesis

individual compounds for chemical analysis using nuclear
magnetic resonance (NMR) spectroscopy to characterize the
molecular structures. As we obtain these pure single compounds,
we will test them individually and in combination to assess
their ability to enhance adipocyte development, both in
vitro and in vivo. Nevertheless, our novel observations have
conclusively determined that compounds related to quercetin
and chlorogenic acid do not mediate SCO’s adipogenic
effects. In addition to enhancing adipogenesis, SCO can exert
beneficial effects on endocrine function, inflammation (10, 11),
and lipolysis (12) in mature adipocytes; the activity-guided
fractionation approach used in this study can be applied to
determine the components of SCO which contribute to each of
these effects.
In conclusion, our activity-guided fractionation efforts have
revealed the presence of multiple pro- and non-adipogenic
compounds within A. scoparia. While SCO contains several
chlorogenic acid and quercetin derivatives with reported
bioactivity, these compounds are not responsible for the extract’s
pro-adipogenic properties. Active fractions were enriched in
prenylated cinnamic acid derivatives, coumarin monoterpene
ethers, polymethoxyflavones, 6-demethoxycapillarisin, a possible
lignan, and perhaps sesquiterpene lactones. The peaks identified
as prenylated coumaric acids are of particular interest, since
other PCAs have been shown to have effects consistent with
enhancing adipogenesis. In addition, non-overlapping fractions
were found to be active in our adipogenesis assay, indicating
the presence of more than one active compound in SCO.
Although the compounds we have putatively identified in the
pro-adipogenic fractions of SCO are chemically related to
other bioactives shown to have pro-adipogenic or metabolically
beneficial effects, they are not identical and, therefore, it appears
that SCO contains compounds not previously known to have
these effects. The identification of bioactive classes of compounds
within SCO sets the groundwork for the characterization of
single bioactive compounds and the study of their mechanism(s)
of action.
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